Previous 10 | Next 10 |
BRANFORD, Conn., May 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Revenue of $4.9 million for the first quarter 2022, representing a 52%...
IsoPlexis (NASDAQ:ISO) has reported prelim revenue of $4.8M to $4.9M for Q1 (up ~48% to 52% Y/Y). The company expects to report full financial results for the first quarter on May 11, 2022. It also reaffirmed its FY22 guidance, expecting revenue to be in the range of $26M to $27M, representin...
BRANFORD, Conn., April 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), the Superhuman Cell Company, today announced its preliminary unaudited revenue for the first quarter of 2022 and the transition to an integrated commercial and operational st...
Gainers: MedAvail MDVL +61%. Lyra Therapeutics LYRA +27%. Medicenna Therapeutics (MDNA) +25%. Biofrontera BFRI +23%. IsoPlexis (ISO) +8%. Losers: BioCryst Pharmaceuticals BCRX -33%. Sunshine Biopharma SBFM -33%. Werewolf Therapeutics (HOWL) -15%. I...
BRANFORD, Conn., April 08, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO ), the Superhuman Cell Company, today announced that data generated using its Duomic™ platform demonstrates the ability to connect T Cell Receptor (TCR) diversity to the most functiona...
Vancouver, Kelowna, Delta, BC - March 25, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Cybersecurity and Cannabis. Today's stocks have been added to our lists of free...
IsoPlexis Corporation (ISO) Q4 2021 Earnings Conference Call March 2, 2022 8:30 AM ET Company Participants Carrie Mendivil – Investor Relations Sean Mackay – Chief Executive Officer John Strahley – Chief Financial Officer Conference Call Participants Max Masucci – ...
The following slide deck was published by IsoPlexis Corporation in conjunction with their 2021 Q4 earnings call. For further details see: IsoPlexis Corporation 2021 Q4 - Results - Earnings Call Presentation
IsoPlexis press release (NASDAQ:ISO): FY GAAP EPS of -$8.99. Revenue of $17.25M (+66.2% Y/Y) beats by $0.13M. 2022 Guidance: IsoPlexis expects full year 2022 revenue to be in the range of $26 million to $27 million, representing 51% to 56% growth over full year 2021. For further detail...
BRANFORD, Conn., March 02, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter and year ended December 31, 2021. Recent Highlights Revenue of $5.5 million for the fourth quarter and $17.3 m...
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) IsoEnergy Limited (TSX-V:ISO) president Tim Gabruch, delves into the strategic merger with Consolidated Uranium, marking a pivotal transformation into a global uranium industry contender. In an interview with Proactive's Angela Harmantas at PDAC 2024, Gabruch noted that t...
SASKATOON, Saskatchewan, Jan. 19, 2024 (GLOBE NEWSWIRE) -- IsoEnergy Ltd. (“IsoEnergy” or the “Company”) (TSXV: ISO; OTCQX: ISENF) is pleased to announce that it has entered into an amended agreement with Eight Capital, as co-lead underwriter and joint bookrunner o...
SASKATOON, Saskatchewan, Jan. 18, 2024 (GLOBE NEWSWIRE) -- IsoEnergy Ltd. (“IsoEnergy” or the “Company”) (TSXV: ISO; OTCQX: ISENF) is pleased to announce that it has entered into an agreement with Eight Capital to act as co-lead underwriter and joint bookrunner on ...